Group 1 - The core viewpoint of the article is that Yiming Pharmaceutical (002826) expects a significant increase in net profit for the fiscal year 2025, projecting a range of 74 million to 102 million yuan, which represents a growth of 61.12% to 122.08% compared to the previous year [1]

Group 1 - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder after the completion of the restructuring [3] - Baiyin Nonferrous Metals reported that the revenue from gold and silver products accounted for a low proportion of total operating income, with gold sales contributing 18.67% and silver sales 4.54% in the first half of 2025 [4] - Tiens Wind Power decided to implement a long-term production suspension for six wholly-owned subsidiaries to optimize resource allocation and focus on core businesses [5] Group 2 - Tongling Nonferrous Metals indicated significant uncertainty in the price fluctuations of its main products, with a low self-sufficiency rate for copper concentrate posing supply stability risks [6] - *ST Aowei received a notice of termination of listing due to its market capitalization falling below 500 million yuan for twenty consecutive trading days [7] - Foton Motor expects a net profit increase of approximately 1551% year-on-year for 2025, driven by sales growth in new energy vehicles and overseas markets [9] Group 3 - Beimo High-tech anticipates a net profit increase of 1076.16% to 1261.87% for 2025, supported by cost control and reduced credit impairment losses [10] - Zhongke Sanhuan forecasts a net profit growth of 566.23% to 899.35% for 2025, attributed to technological innovation and improved operational efficiency [12] - Wancheng Group expects a net profit increase of 222.38% to 266.94% for 2025, driven by growth in its retail business and improved sales margins [13] Group 4 - Huayi Technology anticipates a net profit increase of 191.52% to 330.34% for 2025, benefiting from product optimization and cost reduction measures [14] - Nanmo Biology expects a net profit growth of 269.49% to 423.44% for 2025, supported by increased revenue in the biopharmaceutical sector and improved cost control [15] - Baiao Saitu forecasts a net profit increase of 384.26% to 443.88% for 2025, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [16] Group 5 - Hailanxin expects a net profit increase of 387.47% to 631.2% for 2025, supported by advancements in technology and increased market share in marine observation [17] - Panjiang Co. anticipates a net profit growth of 205.3% to 264.83% for 2025, driven by increased coal production and reduced costs [18] - Huaguang New Materials expects a net profit increase of 104.67% to 141.88% for 2025, with significant growth in the electronic sector [20] Group 6 - Guo Sheng Securities forecasts a net profit increase of 25.44% to 67.25% for 2025, supported by active capital market participation and growth in various business segments [25] - Shengyi Technology expects a net profit growth of 87% to 98% for 2025, driven by increased sales of copper-clad laminates [26] - Sifutian anticipates a net loss of 30 million to 45 million yuan for 2025, although this represents a significant reduction in losses compared to the previous year [27] Group 7 - Maanshan Steel expects a net loss of 1.9 billion to 2.5 billion yuan for 2025, with a substantial reduction in losses compared to the previous year [28] - Shennong Seed Industry forecasts a net profit of 90 million to 120 million yuan for 2025, marking a turnaround from previous losses [30] - Jifeng Co. anticipates a net profit of 410 million to 495 million yuan for 2025, achieving a turnaround from losses [31]

Core Viewpoint - The company expects a net profit of 74 million to 102 million yuan for the fiscal year 2025, representing a year-on-year growth of 61.12% to 122.08% [1] Group 1: Financial Performance - The company is focusing resources on the development of self-produced products, which has led to an increase in the sales volume of its core proprietary product, Miglitol tablets, thereby boosting overall profits [1] - Non-recurring gains and losses are primarily derived from government subsidies and compensation payments from the performance commitments of Bostai, with an estimated impact of 43 million yuan on the company's net profit [1]

证券代码：002826 证券简称：易明医药 公告编号：2026-001 西藏易明西雅医药科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 | 项 | 目 | 本报告期 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 | | | 7,400 | ～ | 10,200 | 4,592.88 | | 股东的净利润 | | 比上年同期增长 | 61.12% | ～ | 122.08% | | | 扣除非经常性损益 | | | 3,900 | ～ | 5,400 | 1,844.67 | | 后的净利润 | | 比上年同期增长 | 111.42% | ～ | 192.74% | | | 基本每股收益（元/股） | | | 0.40 | ～ | 0.56 | 0.25 | 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。但 公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与会计 ...

证券日报网讯1月22日，易明医药（002826）在互动平台回答投资者提问时表示，截至2026年1月20日， 本公司股东数为18392户。 ...

证券日报网讯 1月14日，易明医药在互动平台回答投资者提问时表示，截至2026年1月9日，公司股东数 为18668户。 （文章来源：证券日报） ...

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the five-day moving average, with a change of -0.03% [1] - The total trading volume of A-shares is 18505.22 billion yuan, with 228 A-shares breaking through the five-day moving average [1] Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Dapeng Industrial (证券代: 920091) with a deviation of 8.06% and a price increase of 10.14% [1] - Hongxing Development (证券代: 600367) with a deviation of 7.42% and a price increase of 10.01% [1] - Prologis Pharmaceutical (证券代: 000739) with a deviation of 7.37% and a price increase of 10.03% [1] Additional Notable Stocks - Other notable stocks with significant price movements include: - Lek Electric (证券代: 603355) with a deviation of 7.20% and a price increase of 9.99% [1] - Tianyi Medical (证券代: 301097) with a deviation of 6.87% and a price increase of 11.59% [1] - Meihu Co., Ltd. (证券代: 603319) with a deviation of 6.30% and a price increase of 7.73% [1] Stocks with Smaller Deviations - Stocks that have just crossed the five-day moving average with smaller deviations include: - Cangge Mining (证券代: 300300) with a deviation of 3.83% and a price increase of 5.01% [1] - ST Xiangxue (证券代: 300147) with a deviation of 3.57% and a price increase of 4.79% [1] - Shandong Molong (证券代: 002490) with a deviation of 3.43% and a price increase of 5.62% [1]

证券日报网讯1月6日，易明医药（002826）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东数为18111户。 ...

责任编辑：小浪快报 第2笔成交价格为18.07元，成交77.00万股，成交金额1,391.39万元，溢价率为-1.69%，买方营业部为中 国中金财富证券有限公司上海黄浦区湖滨路证券营业部，卖方营业部为西南证券股份有限公司湖南分公 司。 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为3035.76万元。该股近5个交易日累 计上涨1.94%，主力资金合计净流出566.03万元。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月31日，易明医药收涨1.72%，收盘价为18.38元，发生2笔大宗交易，合计成交量168万股，成交金额 3035.76万元。 第1笔成交价格为18.07元，成交91.00万股，成交金额1,644.37万元，溢价率为-1.69%，买方营业部为华 林证券股份有限公司深圳分公司，卖方营业部为西南证券股份有限公司湖南分公司。 ...

证券日报网讯12月24日，易明医药（002826）在互动平台回答投资者提问时表示，截至2025年12月19 日，公司股东数为18066户。 ...